I know this may not be an apples-to-apples comparison, but do you see PCYC's approach in targeting a Factor VIIa inhibitor for cancer as similar in any way to what MNTA is doing with the M402 cancer program? Also, just curious if you or any others have any comments about the rationale behind PCYC's approach to treating cancer this way. Does this seem feasible?